Stipple Bio Signs Up to $5.9B Oncology Deal With Eli Lilly
Eli Lilly has partnered with private biotech firm Stipple Bio on an oncology research deal potentially worth up to $5.9B. Stipple's technology aims to identify cancer-specific molecules, aiding Lilly's development of targeted therapies. Stipple will receive milestone payments, royalties, and an equity investment, while Lilly gains exclusive rights to resulting products. Stipple is also developing its own oncology pipeline, including STP-100, set for Phase 1 trials in 2027.
How this was made

The 30-second read
Why it matters
The deal provides Lilly exclusive worldwide rights to products emerging from Stipple’s platform, while Stipple gains milestone-driven economics and an equity investment, signaling validation of the platform’s tumor-specific epitope binder approach.
Market read
Traders may reassess Lilly’s oncology pipeline optionality and biotech dealflow expectations based on a large milestone licensing agreement.
What to watch
No disclosed upfront payment size or equity amount, and the lead asset STP-100 is only planned for Phase 1 in early 2027, so timing risk is high.
Background
Stipple Bio is emerging from stealth with its Pointillist Platform and a lead antibody-drug conjugate candidate (STP-100), while Lilly is expanding beyond diabetes and obesity into oncology.
Ticker impact
Eli Lilly signed an oncology research and licensing deal with Stipple Bio, with milestone payments up to $5.9B and exclusive worldwide commercialization rights.
Likely modest positive bias as investors price in expanded oncology R&D optionality and potential future product upside.
The article discloses a large headline deal value and exclusivity, but it does not provide financial terms for Lilly’s upfront or equity size, limiting near-term earnings impact visibility.
Market effects
Reinforces continued big-pharma willingness to pay for precision oncology discovery platforms and ADC-adjacent technologies.
Limited direct regional impact; primarily affects US large-cap pharma sentiment and biotech dealflow expectations.
Global oncology licensing and platform dealmaking remains active, supporting cross-border BD appetite.
Counterpoint
The $5.9B figure is milestone-based and may not translate into near-term cash flows or clinical success; investors may discount the probability-weighted value.
Key entities
- companyEli Lilly
US-listed pharma partner receiving exclusive worldwide rights and funding access to Stipple’s oncology discovery technology.
- companyStipple Bio
Privately held biotech eligible for up to $5.9B in milestone payments and tiered royalties, plus an upfront payment and Lilly equity investment.
- productSTP-100
Stipple’s lead antibody-drug conjugate candidate planned to enter Phase 1 in early 2027 for solid tumors.
- technologyPointillist Platform
Stipple’s platform intended to identify molecules distinguishing cancer cells from healthy tissue via tumor-specific cell-surface epitope binders.

